Suprachoroidal Approach to Treating Uveitic Macular Edema
Approved in the U.S. KEY HIGHLIGHTS:
FIRST commercial product developed by Clearside
FIRST approved therapeutic delivered into the suprachoroidal space
FIRST therapy for macular edema associated with uveitis
FIRST uveitis trial using visual acuity change as a primary endpoint (Phase 3 PEACHTREE)
ABOUT XIPERE™ (triamcinolone acetonide injectable suspension), for suprachoroidal use
XIPERE is a proprietary suspension of the corticosteroid triamcinolone acetonide for use with the SCS Microinjector® and indicated for the treatment of macular edema associated with uveitis.
XIPERE has received U.S. FDA approval. Please see Important Safety Information for XIPERE in the Accompanying Full Prescribing Information here.
Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC), has the exclusive license for the commercialization and development of XIPERE in the United States and Canada.
By clicking this box, you acknowledge that you are leaving the Clearside Biomedical website
Arctic Vision, a specialty ophthalmology company based in China, has the exclusive license for the commercialization and development of XIPERE in Greater China, South Korea, Australia, New Zealand, India and the ASEAN Countries.
About Uveitis and Macular Edema
Uveitis is a set of ocular inflammatory conditions and is one of the leading causes of vision loss, affecting approximately 350,000 patients in the United States and more than one million worldwide. Approximately one-third of these patients develop uveitic macular edema, a build-up of fluid in the macula, the area of the retina responsible for sharp, central vision. Macular edema is the leading cause of vision loss and blindness in uveitis patients and can occur from uveitis affecting any anatomic location – anterior, intermediate, posterior or pan. Learn more from the American Academy of Ophthalmology.